"Designing Growth Strategies is in our DNA"
The global immunoglobulin market size was valued at USD 15.05 billion in 2022 and is projected to grow from USD 16.24 billion in 2023 to USD 29.57 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period.
Increasing prevalence of primary and secondary immunodeficiency and others is increasing demand for available treatment options globally. Along with this, amplification of anti-inflammatory properties and immunomodulatory properties of immunoglobulins has also surged the adoption of these blood products for disorders such as primary immune deficiencies, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and others.
Apart from this, increasing number of patients suffering from auto-immune disorders such as Guillain-Barré Syndrome and IVIG and clinical efficiency of immunoglobulin for the treatment of these conditions lead to increased demand for these products. Thus, the rising prevalence of key disorders along with advancement in treatment options with this product is resulting in an increased demand and adoption rate of the product and alternatively assisting in the immunoglobulin market growth.
The COVID-19 pandemic negatively affected the market growth during the forecast period. Stringent lockdown scenarios along with strict restrictions resulted in the decrease in plasma collection around the globe. This is leading to a shortage of plasma for plasma fractionation.
As a result, the key players were facing difficulties while collecting plasma for plasma fractionation. Hence, the patients were having difficulties accessing plasma products, including immunoglobulin due to a significant shortage. This led to decreased adoption and hindered the growth of the market.
Along with this, reduced inpatient visits and postponement of elective procedures by the governments of many countries significantly decreased hospital admissions for immunology-related disorders. This also led to decreased demand and adoption of these treatment options and hindered market growth during the pandemic.
However, resumption of postponed treatment procedures and ease in lockdown restrictions increased the volume of plasma collection significantly during the post-pandemic. This resulted in an increased supply of plasma products and fueled the growth during the post-pandemic period.
Request a Free sample to learn more about this report.
Shifting Consumer Preference toward Subcutaneous Products to Foster the Growth
The most preferred route of administration is the intravenous route. However, due to a number of limitations such as higher cost, requirement of trained professionals, risk of systemic infection, and requirement of extended duration of observation post-injection are limiting the adoption rate of intravenous dosage formulas.
On the other hand, certain benefits such as better patient compliance, less painful processes, and a large number of injection sites for multiple doses are improving the patient’s preference toward the subcutaneous route of injection.
Along with this, rising number of launches by major players and ongoing research and development activities are fueling the adoption rate of Subcutaneous Immunoglobulin (SCIG) during the study period.
The global prevalence of a number of immunodeficiency disorders, including leukemia, hepatitis, multiple myeloma, and others is increasing the demand for treatment options such as immunoglobulin.
Apart from this, according to a number of research articles, it was reported that the geriatric population is more prone to auto-immune disorders. Therefore, the rising geriatric population is resulting in a large patient pool suffering from this disorder, thus requiring treatment.
This, along with increasing investments by major players for introducing advanced therapy options and adopting a number of organic and inorganic growth strategies foster product adoption.
Henceforth, prevalence coupled with the introduction of advanced products by major players has been instrumental in the market growth during the study period.
Growing prevalence of immunological disorders along with the increasing number of drugs in the market for treatment is fueling the market growth. However, the high cost associated with this therapy is limiting its adoption significantly.
These high costs coupled with limited insurance coverage in South Africa is restricting the adoption rate of plasma products.
Thus, higher costs associated with inadequate reimbursement policies are expected to restrict the adoption of these products among the global population.
Higher Demand for Intravenous Products Led to Segmental Dominance
On the basis of route of administration, the market is segmented into intravenous and subcutaneous.
Comparatively higher demand for intravenous products for immunodeficiency disorders was responsible for the highest share in the intravenous segment. Additionally, certain distinct advantages, including rapid exposure and minimal volume constraints among others are some of the primary factors for the dominance of this segment over subcutaneous products.
On the other hand, the subcutaneous segment is expected to grow with the highest CAGR owing to several factors, including significant cost reduction, self-administration capabilities, and a comparatively lower risk of systemic infections.
To know how our report can help streamline your business, Speak to Analyst
Increasing Usage of these Drugs for Primary Immunodeficiency Resulted in the Segmental Dominance
On the basis of indication, the market is segmented into primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, immune thrombocytopenic purpura, multifocal motor neuropathy, and others.
Increasing prevalence of a number of primary immunodeficiency diseases and the higher consumption of this plasma product for these disorders were responsible for the dominance of this segment.
On the other hand, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) segment is anticipated to grow with a significant CAGR during the study period. Strong focus of key players for introducing advanced drugs in the treatment of CIDP is one of the major reasons for the growth of the segment.
Cost-effectiveness of Liquid Form Led to Segmental Dominance
Based on form, the market is segmented into liquid and lyophilized.
The rising prevalence of auto-immune disorders and the increasing number of immunoglobulin therapy options in the liquid form are the key factors for the adoption of liquid form around the globe. This coupled with cost-effectiveness of this drug form and no requirement for further dilution is another factor for the highest demand and adoption of liquid form over the study period.
On the other hand, the lyophilized segment is anticipated to grow with a moderate CAGR owing to the high cost of lyophilized form and limited number of products available in the market.
Hospital Segment to Dominate Owing to the Availability of Surveillance by Healthcare Professionals
Based on end-user, the market is segmented into hospitals, clinics, and homecare. Presence of advanced healthcare infrastructure and round-the-clock surveillance by healthcare professionals are some of the major reasons for the dominance of the segment. Apart from that, the increasing number of hospital settings in developed and emerging countries is catering to the healthcare needs of the common people, and thus leading to an increasing number of inpatient admission.
On the other hand, the homecare segment is expected to grow with a significant CAGR during the forecast period. Rising preference for the common people toward homecare settings coupled with increasing initiatives by the major players for introducing homecare equipment are fostering the growth opportunity for this segment during the forecast period.
What are the Factors Responsible for the Dominance of North America in the Global Market?
The North America market was valued at USD 9.00 billion in 2022 and is set to dominate the global immunoglobulin market share during the study period. Increasing initiatives for the introduction of drugs by leading players and the availability of insurance coverage are fueling the market growth in this region during the study period.
On the other hand, the rising number of key immunological disorders in key European countries, including Germany, the U.K., and France is fostering the adoption of this plasma product for treatment.
Asia Pacific is expected to grow with the highest CAGR during the forecast period owing to rising healthcare reforms, government initiatives to provide costly IG therapies at an affordable cost, and increasing healthcare expenditure. The current consumption of immunoglobulin per person is significantly lower in Japan, India, and other Southeast Asia countries. However, the increasing number of patients suffering from immunodeficiencies and the availability of reimbursement for these drugs are poised to drive consumption during the forecast period.
Latin America and the Middle East & Africa are anticipated to grow with a moderate CAGR during the study period. Increasing product awareness, rising number of healthcare professionals for this therapy, and increasing product availability in these regions are expected to surge the demand and adoption of this product during the forecast period.
The global market is consolidated with a few major players, including Grifols, S.A., CSL Limited, and Takeda Pharmaceutical Company Limited holding the market's maximum share.
Increasing initiatives for inorganic growth by these major players to expand their product portfolio and brand presence is one of the major factors contributing to the growing market share of these players.
Some of the market players, including Octapharma AG, Kedrion Biopharma, and others were focusing on clinical trials and new product development to cater to the ongoing demand for this product in the global market. This enabled these companies to hold a significant market share in 2022.
The other companies operating in the market are Bio Products Laboratory Ltd., LFB Group, Biotest AG, Shanghai RAAS, and China Biologic Products Holdings, Inc. (TAIBANG BIOLOGIC GROUP).
An Infographic Representation of Immunoglobulins Market
To get information on various segments, share your queries with us
The global immunoglobulin market research report covers a detailed market analysis and overview. It focuses on key aspects such as competitive landscape, product type, and indication. Besides this, it offers insights into the market trends, market dynamics, COVID-19 impact on the market, and other key insights. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market's growth in recent years.
CAGR of 8.9% from 2023-2030
Value (USD billion)
By Route of Administration, Indication, Form, End-user, and Region
By Route of Administration
Fortune Business Insights says that the global market stood at USD 15.05 billion in 2022 and is projected to reach USD 29.57 billion by 2030.
In 2022, the market value stood at USD 15.05 billion.
The market will exhibit steady growth at a CAGR of 8.9% during the forecast period (2023-2030).
By indication, the Primary Immunodeficiency (PI) segment will lead the market.
The rising prevalence of key immunodeficiency disorders and increasing R&D investments to introduce advanced products are the key drivers of the market.
Grifols, S.A., CSL Limited, and Takeda Pharmaceutical Company Limited are the major players in the market.
“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”- U.S.-based biotechnology company focussing on treatment of chronic pain.
“Kudos to your team. Thank you very much for your support and agility to answer our questions.”- Europe-based provider of solutions to automate data centre operations.
“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”- India-based manufacturer of industrial and specialty intermediates with a strong global presence.
“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”- One of the largest cosmetics company in the world.
“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”- U.S. based startup operating in the cultivated meat market.
“We received the below report on the U.S. market from you. We were very satisfied with the report.”- UGlobal hearing aids manufacturer.
“I just finished my first pass-through of the report. Great work! Thank you!”- U.S. based solar racking solutions provider.
“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”- World’s leading advisory firm.
“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”- Germany based machine construction company.
“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”- Japanese manufacturing company of stationery products.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry